We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.73B
AUM Growth
-$549M
Cap. Flow
-$263M
Cap. Flow %
-15.18%
Top 10 Hldgs %
58.51%
Holding
67
New
10
Increased
11
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$68.1M
2
AXSM icon
Axsome Therapeutics
AXSM
+$29.6M
3
ALMS
Alumis Inc
ALMS
+$28.6M
4
PCVX icon
Vaxcyte
PCVX
+$28.2M
5
CGEM icon
Cullinan Oncology
CGEM
+$24M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$107M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$55.1M
3
AUTL
Autolus Therapeutics
AUTL
+$42.2M
4
BBIO icon
BridgeBio Pharma
BBIO
+$36.8M
5
ALXO icon
ALX Oncology
ALXO
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.56B
$373M 21.58%
8,494,151
– –
CRBP icon
2
Corbus Pharmaceuticals
CRBP
$165M
$91.6M 5.29%
2,025,000
– –
ACLX
3
DELISTED
Arcellx
ACLX
$84.2M 4.86%
1,525,000
-255,000
-14% -$13.9M
PCVX icon
4
Vaxcyte
PCVX
$7.65B
$83.1M 4.8%
1,100,000
+415,000
+61% +$28.2M
LBPH
5
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$75.4M 4.36%
2,790,462
-562,679
-17% -$11.1M
EYPT icon
6
EyePoint Inc
EYPT
$999M
$72.4M 4.18%
8,325,000
+1,431,765
+21% +$20M
RAPP
7
Rapport Therapeutics
RAPP
$1.96B
$68.4M 3.95%
+2,940,283
New +$68.1M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.88B
$60.5M 3.49%
1,350,000
+200,000
+17% +$9.24M
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.28B
$54.1M 3.13%
3,006,534
– –
MRUS
10
DELISTED
Merus
MRUS
$49.7M 2.87%
840,000
+125,000
+17% +$6.05M
BBIO icon
11
BridgeBio Pharma
BBIO
$16.4B
$47.1M 2.72%
1,858,351
-1,344,678
-42% -$36.8M
INSM icon
12
Insmed
INSM
$22.4B
$45.2M 2.61%
675,000
+100,000
+17% +$3.88M
NAMS icon
13
NewAmsterdam Pharma
NAMS
$3.26B
$44.2M 2.55%
2,300,000
+800,000
+53% +$16M
JANX icon
14
Janux Therapeutics
JANX
$912M
$44M 2.54%
1,050,000
+300,000
+40% +$14.1M
AXSM icon
15
Axsome Therapeutics
AXSM
$11.7B
$32.2M 1.86%
+400,000
New +$29.6M
CGON icon
16
CG Oncology
CGON
$6.1B
$30.8M 1.78%
975,000
+175,000
+22% +$6.07M
BBOT
17
BridgeBio Oncology
BBOT
$659M
$29.7M 1.72%
2,909,000
– –
ALMS
18
Alumis Inc
ALMS
$3.36B
$28.6M 1.65%
+2,147,400
New +$28.6M
PRAX icon
19
Praxis Precision Medicines
PRAX
$8.11B
$28.3M 1.64%
685,000
-625,000
-48% -$29.5M
ABVX
20
Abivax
ABVX
$10.4B
$28.2M 1.63%
2,130,000
– –
BHVN icon
21
Biohaven
BHVN
$2.02B
$27.8M 1.61%
801,963
+185,000
+30% +$7.31M
URGN icon
22
UroGen Pharma
URGN
$1.97B
$27.7M 1.6%
+1,650,000
New +$23.5M
PHVS icon
23
Pharvaris
PHVS
$2.28B
$27.6M 1.59%
1,466,460
-245,000
-14% -$4.99M
ARQT icon
24
Arcutis Biotherapeutics
ARQT
$3.48B
$23.5M 1.36%
2,525,000
+400,000
+19% +$3.62M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.64B
$19.8M 1.14%
+125,000
New +$16.1M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Cormorant Asset Management held 67 positions worth $1.73B, down 24% from $2.28B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $263M in Q2 2024, closing 18 positions and reducing 11 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Rapport Therapeutics worth $68.4M.

  • Cormorant Asset Management's largest Q2 2024 buy was Rapport Therapeutics: 2,940,283 shares worth $68.4M.
  • Cormorant Asset Management added most to Vaxcyte in Q2 2024, an estimated $28.2M increase.
  • Cormorant Asset Management's biggest Q2 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $55.1M.
  • Cormorant Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $107M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.73B portfolio in Q2 2024.
  • Cormorant Asset Management opened 10 new positions and closed 18 in Q2 2024.
  • Cormorant Asset Management's portfolio value fell 24% quarter-over-quarter to $1.73B.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.